AAAAAA

   
Results: 1-3 |
Results: 3
COMPARISON OF THE PHARMACOKINETICS OF DOLASETRON AND ITS MAJOR ACTIVEMETABOLITE, REDUCED DOLASETRON, IN DOG
Authors: DOW J DIFRANCESCO GF BERG C
Citation: J. Dow et al., COMPARISON OF THE PHARMACOKINETICS OF DOLASETRON AND ITS MAJOR ACTIVEMETABOLITE, REDUCED DOLASETRON, IN DOG, Journal of pharmaceutical sciences, 85(7), 1996, pp. 685-689
PHARMACOKINETICS AND PHARMACODYNAMICS OF THE ACETYLCHOLINESTERASE INHIBITOR 2,2,2-TRIFLUORO-1-(3-TRIMETHYLSILYLPHENYL) ETHANONE IN DOG - POTENTIAL FOR TRANSDERMAL PATCH DELIVERY
Authors: DOW J DULERY BD HORNSPERGER JM DIFRANCESCO GF KESHARY P HAEGELE KD
Citation: J. Dow et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF THE ACETYLCHOLINESTERASE INHIBITOR 2,2,2-TRIFLUORO-1-(3-TRIMETHYLSILYLPHENYL) ETHANONE IN DOG - POTENTIAL FOR TRANSDERMAL PATCH DELIVERY, Arzneimittel-Forschung, 45-2(12), 1995, pp. 1245-1252
ARE THE CARDIOVASCULAR EFFECTS AND 5-HT SYNDROME INDUCED BY MDL-73,975 AND FLESINOXAN IN THE DOG MEDIATED BY 5-HT1A RECEPTORS
Authors: DIFRANCESCO GF
Citation: Gf. Difrancesco, ARE THE CARDIOVASCULAR EFFECTS AND 5-HT SYNDROME INDUCED BY MDL-73,975 AND FLESINOXAN IN THE DOG MEDIATED BY 5-HT1A RECEPTORS, European journal of pharmacology, 262(3), 1994, pp. 205-215
Risultati: 1-3 |